In a 2-year clinical trial of relapsing MS patients, 627 people were treated with TYSABRI versus 315 with placebo. TYSABRI decreased the average number of relapses per year by 67% compared with placebo (TYSABRI 0.22 vs placebo 0.67).
In addition to the clinical trial, TYSABRI was studied in the ongoing TYSABRI Observational Program (TOP). The TOP study is used to further understand the usage of TYSABRI over an extended length of time. We now have over 10 years of interim results.
SHOWN TO BE EFFECTIVE OVER 10 YEARS
*Compared to average number of relapses in the year before they started TYSABRI (1.99 vs 0.24).
NO NEW SAFETY CONCERNS WERE IDENTIFIED